ALK and non-small cell lung carcinoma: In ALKomas other than NSCLC, a small sample size of phase II studies showed that crizotinib demonstrated antitumor efficacy and achieved a durable response, as anticipated.15 However, there are limited reports on other ALK-positive solid tumors, and the efficacy and safety of alectinib for these tumors have only been described as case reports.16-19 Thus, in this case series, we summarize the efficacy and tolerability of ALK-TKIs (alectinib and crizotinib) in patients with ALKomas.